{"id":"W2988004744","doi":"10.1136/ijgc-2019-esgo.179","title":"P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; PARP inhibitor; Internal medicine; Oncology; Chemotherapy; Placebo; BRCA mutation; Nivolumab; Ovarian cancer; Cancer; Immunotherapy; Poly ADP ribose polymerase; Pathology; Polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001139338,0.001576433,0.002264694,0.0006717856,0.0004118281,0.001079618,0.001130559,0.001973468,0.01992351],"category_scores_gemma":[0.001172111,0.0007484961,0.001326238,0.0005353527,0.001098762,0.001111204,0.0004642509,0.003936774,0.003184306],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006326588,"about_ca_system_score_gemma":0.001214657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001329998,"about_ca_topic_score_gemma":0.00428661,"domain_scores_codex":[0.9996026,0.0001862147,0.00001768568,0.00008490169,0.00003339355,0.00007523881],"domain_scores_gemma":[0.9996359,0.00006782237,0.00007411509,0.00002984024,0.00001986792,0.0001723153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9428503,0.01304084,0.0003432815,0.001394543,0.0007754228,0.00005318773,0.00006683716,0.0003409392,0.006363241,0.0003819517,0.003552962,0.0308365],"study_design_scores_gemma":[0.925091,0.07043072,0.001091799,0.00004856052,0.0002426117,0.0000336021,0.00002191436,0.0002519091,0.0004517842,0.0001909369,0.002127939,0.00001714238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9431944,0.01123617,0.002532698,0.001725605,0.001823463,0.01773349,0.005760449,0.001016831,0.01497683],"genre_scores_gemma":[0.952998,0.006664301,0.003868883,0.002263139,0.0005218485,0.01011358,0.004000875,0.0001449939,0.01942443],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01992351,"threshold_uncertainty_score":0.06665075,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03418808107734086,"score_gpt":0.3591871224557714,"score_spread":0.3249990413784305,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}